NOVEMBER 2013
Health Canada approves Opsumit (macitentan) for sale in Canada for the treatment of PAH

MARCH 2014
Health Canada approves Adempas (riociguat) for sale in Canada for the treatment of PAH

OCTOBER 2014
INESSS recommends Opsumit be added to the list of drugs covered by the prescription drug insurance plan and Quebec begins providing public reimbursement for Opsumit

JANUARY 2015
Common Drug Review (CDR) recommends Opsumit be publicly funded (with criteria and a condition) for the long-term treatment of PAH to reduce morbidity in patients with Functional Class II or III

FEBRUARY 2015
INESSS recommends Adempas not be added to the list of drugs covered by the prescription drug insurance plan and Quebec declines to list Adempas for public funding

MARCH 2015
The ***CADTH Therapeutic Review Recommendation Report of Drugs for PAH*** recommends a suboptimal stepped approach to initial PAH therapy

JUNE 2015
PHA Canada launches an advocacy campaign to ensure all PAH patients have publicly funded access to new and existing treatments at diagnosis and beyond; PHA Canada Ambassadors begin meeting with their local provincial government representatives

SEPTEMBER 2015
Scleroderma Canada (SC) launches an advocacy campaign during National Scleroderma Conference and distributes advocacy postcards to systemic scleroderma-associated PAH (SSc-PAH) patients and supporters across Canada addressed to the provincial Ministers of Health

NOVEMBER 2015
SC and Scleroderma Association of Saskatchewan meet with the Saskatchewan Health Minister to discuss the importance of access to Opsumit for PAH patients, including those with SSc-PAH

DECEMBER 3 2015
PHA Canada and SC host an advocacy day at Queen's Park for Ontarians affected by PAH, including those with SSc-PAH

DECEMBER 2015
CDR recommends Adempas be publicly funded (with criteria and a condition) for the treatment of PAH as monotherapy or in combination with ERAs in adult patients with Functional Class II or III

DECEMBER 2015
Provincial and territorial negotiations for Opsumit through the pan-Canadian Pharmaceutical Alliance (pCPA) are closed without coming to an agreement

JANUARY 2016
Health Canada approves Uptravi (selexipag) for sale in Canada for the treatment of PAH

FEBRUARY 2016
PHA Canada and SC call on pCPA to re-open negotiations for Opsumit without further delay to ensure that all patients living with PAH, including those with SSc-PAH, have publically funded access to optimal treatment for their life-threatening disease

JUNE 2016
MPP Michael Harris delivers 833 postcards from PAH, including SSc-PAH, supporters in Ontario to Honourable Dr. Eric Hoskins, Minister of Health and Long-Term Care

JUNE 2016
SC and Scleroderma Association of Saskatchewan have second meeting with the Saskatchewan Health Minister and deliver 106 postcards from PAH, including SSc-PAH, supporters in the province

JULY 2016
PHA Canada submits recommendations for improving funding criteria for PAH, including SSc-PAH, treatments to Ontario's Ministry of Health and Long-Term Care

OCTOBER 2016
Saskatchewan declines to list Adempas for public funding

OCTOBER 2016
INESSS recommends Uptravi not be added to the list of drugs covered by the prescription drug insurance plan and Quebec declines to list Uptravi for public funding

OCTOBER 2016
CDR recommends Uptravi be publicly funded (with a criterion and a condition) for the long-term treatment of PAH, to delay disease progression in adult patients with Functional Class II or III

DECEMBER 2017
Provincial and territorial pricing negotiations for Uptravi through the pan-Canadian Pharmaceutical Alliance (pCPA) are successfully completed

JANUARY 2018
PHA Canada and SC continue to call on provincial and territorial governments to immediately fund Uptravi through their public drug programs to ensure patients have timely and equitable access to Uptravi

MARCH 2018
Quebec becomes the first province to provide public reimbursement for Uptravi

JUNE 2018
Alberta, Saskatchewan, Manitoba, Ontario and Newfoundland and Labrador have now joined the growing list of provinces to provide public reimbursement for Uptravi. To date, 85 per cent of Canadians have access to this important treatment option.

DECEMBER 2018
British Columbia, New Brunswick, Nova Scotia and Prince Edward Island join the rest of Canada in providing public reimbursement for Uptravi, making Uptravi accessible to the vast majority of Canadians living with PAH.